Their findings suggest that cholinesterase inhibitors (ChEIs) treatment generally improved neuropsychiatric and functional assessment scores in patients with Alzheimer disease (AD). The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.